La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cartesian Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cartesian Therapeutics..

Cartesian Therapeutics (NASDAQ:RNAC) Azioni, Catena delle Opzioni

CARTESIAN THERAPEUTICS INC

Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics Inc

WIIM

Optical Cable Corporation shares are trading lower. The company reported Q2 financial results.

Tempest Therapeutics, Inc. - Common Stock

TPST

Tempest Therapeutics shares are trading higher after the company announced it received orphan drug designation from the EMA for its amezalpat for the treatment of patients with hepatocellular carcinoma

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling around 0.1% points on Thursday.
The Dow traded down 0.06% to 42,400.42 while the NASDAQ fell 0.40% to 19,381.93. The S&amp;P 500 also fell, dropping, 0.27% to 5,954.96.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45744658/jim-cramer-recommends-nvidia-over-very-cheap-semiconductor-stock">Jim Cramer Recommends Nvidia Over &#8216;Very Cheap&#8217; Semiconductor Stock</a>
Leading and Lagging Sectors Communication services shares jumped by 0.4% on Thursday.
In trading on Thursday, consumer discretionary stocks fell by 1.5%.
Top Headline
Ciena Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) reported downbeat earnings for its fiscal second quarter.
The Hanover, Maryland-based company reported a quarterly revenue growth of 23.6% year-on-year to $1.13 billion, beating the analyst consensus estimate of $1.09 billion. The American telecommunications networking equipment and software services supplier reported adjusted EPS of 42 cents, missed the analyst consensus estimate of 52 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Planet Labs PBC &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) shares shot up 51% to $6.03 following a first-quarter sales beat and after the company raised its FY26 sales guidance</li>
<li>Shares of Liminatus Pharma, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) got a boost, surging 64% to $20.86 after the company announced it regained Nasdaq compliance.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares were also up, gaining 17% to $7.78 after the company announced it terminated its Rotech Healthcare acquisition.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) shares dropped 23% to $0.6829 following a first-quarter sales miss and after the company issued second-quarter sales guidance below estimates.</li>
<li>Shares of REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) were down 16% to $8.49 after the company announced new functional data from PHASE I/II Affinity Duchenne&#xAE; trial of RGX-202.</li>
<li>PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) was down, falling 17% to $66.92 after the company cut its FY25 guidance below estimates and issued second-quarter adjusted EPS guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $63.34 while gold traded down 0.8% at $3,373.80.
Silver traded up 3.1% to $35.735 on Thursday, while copper rose 0.7% to $4.9215.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.16%, while Spain's IBEX 35 Index rose 0.73%. London's FTSE 100 rose 0.11%, Germany's DAX 40 gained 0.19% and France's CAC 40 fell 0.18% during the session.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei falling 0.51%, Hong Kong's Hang Seng Index jumping 1.07%, China's Shanghai Composite gaining 0.23% and India's BSE Sensex gaining 0.55%.
Economics
<ul class="wp-block-list">
<li>Imports of goods and services into the US fell 16.3% to $351 billion during April.</li>
<li>Unit labour costs in the US nonfarm business sector rose 6.6% during the first quarter.</li>
<li>Exports of goods and services climbed 3% to $289.4 billion in April.</li>
<li>Nonfarm business sector labor productivity in the U.S. declined by 1.5% in the first quarter.</li>
<li>The U.S. trade gap shrank to $61.6 billion in April, recording the lowest level since September 2023.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45790413/lululemon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-2">Lululemon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

CHPT

CIEN

LIMN

RGNX

Crude Oil Moves Higher; Ciena Posts Downbeat Earnings

MAIA Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NASDAQ">MAIA</a>) on Thursday revealed updated data from its THIO-101 pivotal <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45790333/maia-biotechnology-announces-positive-efficacy-update-for-phase-2-thio-101-clinical-trial-in-non-s" rel="noreferrer noopener">Phase 2 clinical trial</a>.
The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">therapy and chemotherapy</a>.
As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis demonstrates a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39909095/maia-biotechnologys-lung-cancer-drug-shows-promising-long-term-benefits-in-advanced-patients" rel="noreferrer noopener">MAIA Biotechnology&#8217;s Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients</a>
The treatment has been generally well-tolerated to date in this heavily pretreated population.
At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival.
Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.
&#8220;This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in the medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape,&#8221; said MAIA Chairman and CEO Vlad Vitoc.
MAIA&#8217;s multiple potential regulatory pathways for ateganosine could provide accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.
The company announced a new partial response (PR) was identified in a patient after 20 months of treatment. A partial response is defined as a decrease in tumor size of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45796236/maia-biotechnology-announces-new-responder-in-non-small-cell-lung-cancer-phase-2-clinical-trial" rel="noreferrer noopener">at least 30%</a>.
&#8220;The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment,&#8221; Vitoc added.
Price Action: MAIA stock is up 11.7% at $1.97 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45800081/dr-reddys-and-alvotech-join-hands-to-develop-biosimilar-for-mercks-blockbuster-cancer-drug">Dr Reddy&#8217;s And Alvotech Join Hands To Develop Biosimilar For Merck&#8217;s Blockbuster Cancer Drug</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

General

MAIA

REGN

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

ImmunoPrecise Antibodies shares are trading higher after the company announced it discovered a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai platform

DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) will release its first-quarter earnings results after the <a href="https://www.benzinga.com/quote/DOCU/earnings">closing bell on Thursday, June 5</a>.
Analysts expect the San Francisco, California-based company to report quarterly earnings at 81 cents per share, down from 82 cents per share in the year-ago period. DocuSign projects to report quarterly revenue at $748.92 million, compared to $709.64 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 29, Docusign named Michael Adams as new Chief Information Security Officer.
DocuSign shares rose 2.4% to close at $93.84 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/docu/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>JMP Securities analyst Patrick Walravens reiterated a Market Outperform rating with a price target of $124 on June 3, 2025. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Karl Keirstead maintained a Neutral rating and cut the price target from $90 to $85 on April 17, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Morgan Stanley analyst Josh Baer maintained an Equal-Weight rating and cut the price target from $97 to $92 on April 16, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Jefferies analyst Brent Thill maintained a Buy rating and slashed the price target from $115 to $105 on March 31, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Citigroup analyst Tyler Radke maintained a Buy rating and raised the price target from $113 to $115 on March 14, 2025. This analyst has an accuracy rate of 71%.</li>
</ul>
Considering buying DOCU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/docu/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04210406/image-59-1024x593.png" alt="" class="wp-image-938974" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04210406/image-59-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04210406/image-59-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04210406/image-59-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04210406/image-59.png 1091w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45767953/jim-cramer-arrowhead-pharmaceuticals-doesnt-have-the-horses">Jim Cramer: Arrowhead Pharmaceuticals Doesn&#8217;t &#8216;Have The Horses&#8217;</a> </li>
</ul>
Photo via Shutterstock

DOCU

DocuSign Likely To Report Higher Q1 Revenue; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

A friendship between President Donald Trump and billionaire Elon Musk may be coming to an end, with a heated <a href="https://www.benzinga.com/news/25/05/45635854/elon-musk-disappointed-with-trumps-big-beautiful-bill-says-it-undermines-the-work-that-the-doge-team-is-doing">public falling out</a> due to the "big beautiful bill."
What Happened: Musk helped the White House administration in the Department of Government Efficiency and was a close ally of Trump during his first 100+ days in<a href="https://www.benzinga.com/news/25/05/45707423/trump-says-he-is-having-elon-musk-over-at-the-white-house-tomorrow-for-a-press-conference-as-billion"> the White House.</a>
The billionaire, who is the world's richest man, publicly endorsed Trump for the 2024 presidential election and donated hundreds of millions to the campaign to get him elected.
The public friendship may now be coming apart, as Musk has vocally opposed the "Big Beautiful Bill," which would increase government spending and debt.
On Thursday, Trump said Musk isn't the first admirer to later turn on him. "It's sorta Trump Derangement Syndrome, they call it," the president said.
Trump said that sometimes people wake up, change their minds, and become hostile toward him.
&#8220;I'm very disappointed because Elon knew the inner workings of this bill better than almost anybody sitting here&#8230; He had no problem with it, all of the sudden he had a problem, and he only developed a problem when he found out that we&#8217;re going to have to cut the EV mandate.&#8221; 
Trump said while Musk hasn't said anything bad about him personally, he thinks that could be next.
"I'm very disappointed in Elon."
Trump added that the EV mandate would provide money to help the sector, which is "having a hard time." The president also said Musk wanted someone "he knew very well" to head NASA, a likely reference to Jared Isaacman, who Trump recently withdrew as the NASA administrator nominee.
Musk took to social media platform X to share his side of the story.
"False, this bill was never shown to me even once and was passed in the dead of night so fast that almost no one in Congress could even read it!" Musk <a href="https://x.com/elonmusk/status/1930662301792977094">tweeted</a>.
Another <a href="https://x.com/elonmusk/status/1930660788739698878">tweet </a>from Musk encouraged Congress to "ditch the mountain of disgusting pork in the bill."
"Either you get a big and ugly bill or a slim and beautiful bill. Slim and beautiful is the way."
Musk also said "whatever" to the EV incentive cuts and said the cuts could be kept in the bill even though oil and gas subsidies weren't cut.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45710022/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-67">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: The latest comments from Trump and Musk come after Musk shared several old tweets from the president on X that could be shading him over his support for the "Big Beautiful Bill."
Musk <a href="https://x.com/elonmusk/status/1930645855285231914">shared </a>an old 2013 tweet of Trump's that read, "I cannot believe the Republicans are extending the debt ceiling – I am a Republican &amp; I am embarrassed."
Musk also <a href="https://x.com/elonmusk/status/1930652448726925524">shared </a>an old 2012 tweet from Trump that said, "No member of Congress should be eligible for re-election if our country's budget is not balanced – deficits not allowed."
The new bill, which is in the Senate and could have changes made, is estimated to add $5 trillion to the national debt in the coming years based on estimates from the Congressional Budget Office.
Things may have escalated further on Thursday when Musk responded to a post in which Trump claimed he would have won the key swing state of Pennsylvania without the billionaire's help.
Musk thinks this is the opposite.
"Without me, Trump would have lost the election, Dems would control the House and the Republicans would be 51-49 in the Senate. Such ingratitude," Musk <a href="https://x.com/elonmusk/status/1930667528696828120">tweeted</a>.
Trump's comments on Thursday suggest the friendship could be over.
"Elon and I had a great relationship. I don't know if we will anymore," Trump said.
TSLA Price Action: Electric vehicle company Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has had <a href="https://www.benzinga.com/25/05/45475999/if-you-invested-1000-in-tesla-stock-when-elon-musk-endorsed-donald-trump-for-president-heres-how-much-youd-have-today">a bumpy road</a> for its stock price with Musk's relationship with the president. The stock soared after Trump's win and fell in 2025 with brand damage done and protests hitting the company and dealerships over Musk's political interests.
Tesla stock fell after Trump's comments Thursday and shares are down 7% to $308.78 at the time of writing. Tesla stock is down 18.8% year-to-date in 2025 with shares down over 13% in the last five days. &nbsp;
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45795080/whatever-you-think-of-elon-musk-you-must-support-his-fight-against-the-big-beautiful-bill-says-black-swan-author-nassim-taleb">&#8216;Whatever You Think Of Elon Musk, You Must Support His Fight Against The Big Beautiful Bill,&#8217; Says &#8216;Black Swan&#8217; Author Nassim Taleb</a></li>
</ul>
Photo: Shutterstock

Politics

TSLA

Trump Says Musk Has 'Trump Derangement Syndrome' As Battle Over Bill Heats Up: 'Had A Great Relationship… Don't Know If We Will Anymore'

Rumors

Nippon Steel Deal For U.S. Steel Seen Closing By Merger Deadline

<a href="https://aws.amazon.com/blogs/aws/announcing-up-to-45-price-reduction-for-amazon-ec2-nvidia-gpu-accelerated-instances/" title="https://aws.amazon.com/blogs/aws/announcing-up-to-45-price-reduction-for-amazon-ec2-nvidia-gpu-accelerated-instances/">https://aws.amazon.com/blogs/aws/announcing-up-to-45-price-reduction-for-amazon-ec2-nvidia-gpu-accelerated-instances/</a>

AMZN

NVDA

AWS Announces Up To 45% Price Reduction For Amazon EC2 NVIDIA GPU-Accelerated Instances

Rocket Companies, Inc. (NYSE:&nbsp;RKT) (the "Company" or "Rocket Companies"), the Detroit-based fintech platform including mortgage, real estate, title and personal finance businesses, today priced its private offering of $2.0 billion aggregate principal amount of 6.125% senior notes due 2030 and $2.0 billion aggregate principal amount of 6.375% senior notes due 2033 (collectively, the "Notes" and such offering, the "Offering").
The Offering is expected to close on June 20, 2025, subject to certain customary conditions.
The Company intends to use the proceeds from the Offering to (i) on the closing date for the Mr. Cooper Acquisition, redeem NMH's 5.000% senior notes due 2026, 6.000% senior notes due 2027 and 5.500% senior notes due 2028 at redemption prices equal to 100% of the principal amount of such notes, plus accrued and unpaid interest to, but excluding, the redemption date (the "Redemption"), (ii) pay fees and expenses related to the Offering and the Redemption, (iii) at the Company's discretion, redeem, purchase (including, if required, in a change of control offer) and/or amend NMH's 6.500% senior notes due 2029, 5.125% senior notes due 2030, 5.750% senior notes due 2031 and 7.125% senior notes due 2032 and pay fees and expenses in connection therewith and (iv) after the consummation of the Mr. Cooper Acquisition, repay secured debt of the Company and its subsidiaries (including Redfin, Mr. Cooper and their subsidiaries).

Rocket Companies Prices $4B Private Offering Of Senior Notes: $2B At 6.125% Due 2030, $2B At 6.375% Due 2033

CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading sideways on Thursday. But over the past week, <a href="https://www.benzinga.com/markets/equities/25/06/45793442/crowdstrike-ceo-defends-financial-reporting-amid-doj-probe-into-global-it-outage-says-we-stand-by-the-accounting-of-those-transactions">the shares have been extremely volatile</a>. 
Despite this, the stock demonstrated a principle of technical analysis. This is why our technical analysis team has made it our Stock of the Day.
The best traders can identify important price levels in markets. These levels are called support and resistance.
If a stock is trending lower, it is because there isn't enough demand to absorb all of the supply. There are more shares for sale than there are to be bought. This forces sellers to be aggressive and undercut each other's prices and it puts the shares into a downtrend.
At a support level, there is enough demand to absorb all of the supply. This is why sell-offs end or pause when they reach support.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05140149/CrowdStrike.june2025.one_-1024x571.png" alt="" class="wp-image-940172" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05140149/CrowdStrike.june2025.one_-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05140149/CrowdStrike.june2025.one_-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05140149/CrowdStrike.june2025.one_-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05140149/CrowdStrike.june2025.one_.png 1474w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/commodities/25/06/45792880/silver-hits-12-year-high-peter-schiff-says-rallys-just-starting">Silver Hits 12-Year High: Peter Schiff Says Rally&#8217;s Just Starting</a>
If a stock is moving higher, it&#8217;s because there is more demand than supply. There are more shares to be bought than there are for sale. Buyers are forced to cut in front of each other and outbid each other if they wish to acquire shares. This makes the stock move higher.
In the markets, what had been resistance can turn into support. This is a common occurrence and can be seen on the CrowdStrike chart.
Yesterday, the stock dropped to around $445. This was the low of the day and it was where there was support. There was support here because the level had been resistance.
Some of the people who sold around $445 regretted doing so after the resistance broke. Many decided to buy their shares back at their selling prices yesterday when CrowdStrike dropped to this level. This formed support.
Now there is support for the shares around $456. This can also be seen on the chart. This level had also been resistance.
In the financial markets, certain price levels have more importance than others. Good traders know how to identify them. This gives them an indication of where a trend may reverse.
Read Next: • <a href="https://www.benzinga.com/markets/market-summary/25/06/45798808/trump-announces-china-trade-talks-tesla-stock-slumps-whats-driving-markets-thursday">Trump Announces China Trade Talks, Tesla Stock Slumps: What&#8217;s Driving Markets Thursday?</a>
Photo: Shutterstock

Technicals

CRWD

Stock Of The Day: Where Is The Bottom In CrowdStrke?

<a href="https://www.philadelphiafed.org/the-economy/monetary-policy/250605-economic-outlook-and-final-thoughts">https://www.philadelphiafed.org/the-economy/monetary-policy/250605-economic-outlook-and-final-thoughts</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Harker Says Estimating Tariff Impact Is A Moving Target; Businesses Community Mainly Wants Stability In Trade Policy At This Point; Fed Faces No Rush To Shrink Size Of Balance Sheet

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics</a>

CLOV

EHTH

ELEV

GOCO

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg

Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) made a powerful entrance onto the New York Stock Exchange on Thursday, with shares of the stablecoin issuer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) opening at $69, more than double <a href="https://www.benzinga.com/markets/offerings/25/06/45785682/chamath-palihapitiya-says-circle-ipo-valued-at-7-billion-means-its-a-genius-buy-for-coinbase-heres-why">its $31 IPO price</a>.
The company raised approximately $1.1 billion through the sale of 34 million shares, securing a valuation of $6.9 billion and marking a major milestone after a previously unsuccessful public listing attempt via SPAC in 2021.
The timing of Circle's debut comes amid broader market uncertainty. 
As earnings season concludes, a majority of companies have offered cautious guidance, suggesting continued pressure on U.S. equities in the near term. 
Despite that backdrop, Circle&#8217;s business model has positioned it to benefit from a growing demand for digital dollars.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45788564/bitcoin-bull-run-on-the-brink-as-long-term-holders-accelerate-profit-taking-report">Bitcoin Bull Run On The Brink As Long-Term Holders Accelerate Profit-Taking: Report</a>
At the heart of the company's operations is USDC, a dollar-backed stablecoin increasingly used in digital payments, cross-border transfers, and corporate treasury management. 
That demand has accelerated in 2025, partly fueled by improving regulatory clarity in the U.S. which is expected to strengthen the legitimacy and utility of stablecoins within traditional finance.
A recent report from Deutsche Bank supports this outlook, suggesting stablecoins are nearing mainstream adoption. 
The bank highlighted their role in reinforcing the global dominance of the U.S. dollar and improving efficiency in international finance.
Circle's public listing is seen by some analysts as more than just a tech IPO, it reflects a broader market belief that stablecoins are evolving into foundational tools for the global financial system.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45777944/jpmorgan-to-accept-crypto-linked-etfs-as-loan-collateral">JPMorgan To Accept Crypto-Linked ETFs As Loan Collateral</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$USDC

CRCL

Circle Surges To $69 In NYSE Debut, Raising $1.1B As Investors Bet On Stablecoins Going Mainstream

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $112 to $125.

Barrington Research Maintains Outperform on HealthEquity, Raises Price Target to $125

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true</a>

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill' -Bloomberg

MEDIROM Healthcare Technologies Regains Nasdaq Compliance On Minimum Bid Price

Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), a stock popularized as a proxy for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), received mixed signals from key technical indicators Thursday.
What happened: According to the market analytics platform TradingView, the simple and exponential moving averages across and above the 30-day timeframe <a href="https://in.tradingview.com/symbols/NASDAQ-MSTR/technicals/">produced </a>a &#8220;Buy&#8221; signal for the stock.
A moving average calculates the average price of a financial instrument over a specific period. If the price is above the moving average, the trend is upward. If the price is below the moving average, the trend is downward. Traders use moving averages to identify entry and exit points.
Moreover, the Bull Bear Power indicator, which measures the strength of buyers and sellers, also signaled &#8220;Buy.&#8221;&nbsp;
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45740537/forget-dollars-willy-woo-says-bitcoin-will-be-priced-against-global-gdp-gold-used-to-be-that-money-btc-is-the-challenger">Forget Dollars: Willy Woo Says Bitcoin Will Be Priced Against Global GDP — &#8216;Gold Used To Be That Money, BTC Is The Challenger&#8217;</a>
InvestXOS, an investment-focused X account, said MSTR was building "serious momentum" with a potential cup and handle formation on the daily chart.
"If it somehow runs past $400 psychological level, we might see a huge, huge b/o," the analyst said, projecting potential price targets at $541, $566 and $582.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">MicroStrategy <a href="https://twitter.com/search?q=%24MSTR&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$MSTR</a> is getting some serious momentum here with this potential cup &amp; handle formation on daily chart&#8230;. if it somehow runs pass 400 psychological level, we might see a huge huge b/o&#8230;. measured move points to 541 566 582 IF b/o does happen&#8230;. <a href="https://t.co/aIvHbWFiKf">pic.twitter.com/aIvHbWFiKf</a>
&mdash; InvestXOS (@InvestXOS) <a href="https://twitter.com/InvestXOS/status/1930396429257695608?ref_src=twsrc%5Etfw">June 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The momentum indicators, however, painted a different story. The Moving Average Convergence Divergence indicator, which plots the relationship between two moving averages—typically a 12-day and a 26-day exponential moving average—flashed "Sell" for MSTR.
Meanwhile, the Relative Strength Index indicator used for spotting overbought or oversold conditions showed a ‘Neutral&#8217; reading for the stock.
On the derivative front, MSTR's Put/Call Ratio was 0.85 as of this writing,&nbsp; <a href="https://fintel.io/sopt/us/mstr">according </a>to Fintel, indicating that bullish bets outnumbered bearish bets.
Why It Matters: Strategy has been at the forefront of Bitcoin's corporate adoption, holding a BTC stockpile worth more than $60.8 billion as of this writing,&nbsp;<a href="https://bitcointreasuries.net/" target="_blank" rel="noreferrer noopener">according</a>&nbsp;to bitcointreasuries.net. 
The stock has seen significant volatility in the last eight months or so. &nbsp;Strategy&#8217;s <a href="https://in.benzinga.com/crypto/cryptocurrency/25/06/45722106/strategy-and-metaplanet-deepen-bitcoin-exposure-with-over-190-million-in-fresh-buys-amid-105k-market-level#:~:text=treasury%20reserve%20asset.-,Strategy%20Inc.,billion%20at%20current%20market%20prices.">corporate strategy of using debt and equity</a> to accumulate Bitcoin makes it highly sensitive to the apex cryptocurrency&#8217;s price swings.&nbsp;
Price Action:&nbsp; At the time of writing, BTC was exchanging hands at $104,905.99, up 0.88% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;
Shares of Strategy were up 0.41% in pre-market trading after closing 2.41% lower at $378.10 during Wednesday's regular trading session.
MSTR demonstrated a very high momentum score—a measure of the stock's relative strength based on its price movement patterns and volatility over multiple timeframes—as of this writing. Want to see which stocks outperformed MSTR in this metric? Visit <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge Stock Rankings</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="447" height="186" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05060907/Screenshot-2025-06-05-153848.png" alt="" class="wp-image-939506" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05060907/Screenshot-2025-06-05-153848.png 447w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05060907/Screenshot-2025-06-05-153848-300x125.png 300w" sizes="(max-width: 447px) 100vw, 447px" /></a></figure>
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45739199/american-politicians-dont-believe-bitcoin-can-co-exist-peacefully-with-the-dollar-says-this-popular-btc-maximalist-heres-why">American Politicians Don&#8217;t Believe Bitcoin Can &#8216;Co-Exist Peacefully&#8217; With The Dollar, Says This Popular BTC Maximalist: Here&#8217;s Why</a></li>
</ul>
Photo courtesy: PJ McDonnell / Shutterstock

$BTC

MSTR

Bitcoin Stock Strategy— Buy Or Sell? What Technicals Reveal For Michael Saylor's MSTR?

Across the recent three months, 11 analysts have shared their insights on ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.45, with a high estimate of $35.00 and a low estimate of $22.00. Witnessing a positive shift, the current average has risen by 14.81% from the previous average price target of $23.91.
<img src="https://www.benzinga.com/files/images/story/2025/1749146492_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of ACADIA Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ACADIA Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for ACADIA Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of ACADIA Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ACAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ACADIA Pharmaceuticals analyst ratings.</a>
<h2>Get to Know ACADIA Pharmaceuticals Better</h2>
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
<h3>ACADIA Pharmaceuticals's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, ACADIA Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 18.7% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.77%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ACADIA Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 2.53%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): ACADIA Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.64%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.07, ACADIA Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts

Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) has been analyzed by 3 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $6.5, a high estimate of $8.00, and a low estimate of $5.50. Marking an increase of 11.49%, the current average surpasses the previous average price target of $5.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1749146483_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Cipher Mining by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.50</td>
<td>$5.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cipher Mining. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cipher Mining compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Cipher Mining's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Cipher Mining's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CIFR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cipher Mining analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Cipher Mining</h2>
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
<h3>Cipher Mining's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Cipher Mining showcased positive performance, achieving a revenue growth rate of 1.71% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Cipher Mining's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -79.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Cipher Mining's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.5%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cipher Mining's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.41%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.08.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CIFR

Cipher Mining Stock: A Deep Dive Into Analyst Perspectives (3 Ratings)

Press Releases

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Comments

Cartesian Therapeutics

Cartesian Therapeutics (RNAC) Opzioni

Cartesian Therapeutics (NASDAQ:RNAC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO